|
US5670347A
(en)
|
1994-05-11 |
1997-09-23 |
Amba Biosciences Llc |
Peptide-mediated gene transfer
|
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
|
US6008202A
(en)
*
|
1995-01-23 |
1999-12-28 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
|
US20030069173A1
(en)
*
|
1998-03-16 |
2003-04-10 |
Life Technologies, Inc. |
Peptide-enhanced transfections
|
|
US6120794A
(en)
*
|
1995-09-26 |
2000-09-19 |
University Of Pittsburgh |
Emulsion and micellar formulations for the delivery of biologically active substances to cells
|
|
US6387700B1
(en)
|
1996-11-04 |
2002-05-14 |
The Reagents Of The University Of Michigan |
Cationic peptides, Cys-Trp-(LYS)n, for gene delivery
|
|
US6894031B1
(en)
*
|
1996-11-21 |
2005-05-17 |
Cedars-Sinai Medical Center |
Pituitary tumor transforming gene (PTTG) carboxy-terminal peptides and methods of use thereof to inhibit neoplastic cellular proliferation and/or transformation
|
|
US7097829B2
(en)
*
|
1996-11-21 |
2006-08-29 |
Cedars-Sinai Medical Center |
Transgenic cells transfected with pituitary tumor transforming gene (PTTG)) expression vectors and uses therefor
|
|
US6913926B2
(en)
*
|
1996-11-21 |
2005-07-05 |
Cedars-Sinai Medical Center |
Method of regulating biological activity of pituitary tumor transforming gene (PTTG)1 using PTTG2
|
|
WO1999053961A1
(en)
*
|
1998-04-23 |
1999-10-28 |
The Regents Of The University Of Michigan |
Peptides for efficient gene transfer
|
|
US6903077B1
(en)
|
1999-01-04 |
2005-06-07 |
University Of Vermont And State Agricultural College |
Methods and products for delivering nucleic acids
|
|
US6770740B1
(en)
|
1999-07-13 |
2004-08-03 |
The Regents Of The University Of Michigan |
Crosslinked DNA condensate compositions and gene delivery methods
|
|
CA2391348A1
(en)
*
|
1999-07-29 |
2001-02-08 |
Assem Ziady |
Enhanced delivery via serpin enzyme complex receptor
|
|
DE50015216D1
(de)
|
1999-11-08 |
2008-07-31 |
Ipf Pharmaceuticals Gmbh |
Humanes zirkulierendes virus inhibierendes peptid (virip) und seine verwendung
|
|
US7355019B2
(en)
*
|
2000-06-06 |
2008-04-08 |
Sibtech, Inc. |
Cysteine-containing peptide tag for site-specific conjugation of proteins
|
|
EP1170373A1
(en)
*
|
2000-07-03 |
2002-01-09 |
Retina France |
Peptide-mediated ocular cell transfection
|
|
US20020182626A1
(en)
*
|
2001-03-16 |
2002-12-05 |
Daniel Tuse |
Episomal non-transforming nucleic acid elements in functional genomic and antigenic applications
|
|
US20030203865A1
(en)
*
|
2001-04-30 |
2003-10-30 |
Pierrot Harvie |
Lipid-comprising drug delivery complexes and methods for their production
|
|
US6909030B2
(en)
*
|
2001-10-15 |
2005-06-21 |
Cedars-Sinai Medical Center |
PTTG knockout rodent as a model to study mechanisms for various physiological phenomena, including diabetes
|
|
WO2004003160A2
(en)
*
|
2002-06-27 |
2004-01-08 |
University Of Washington |
Use of adhesion molecules as bond stress-enhanced nanoscale binding switches
|
|
US20040014704A1
(en)
*
|
2002-07-18 |
2004-01-22 |
Gonzalo Hortelano |
Oral administration of therapeutic agent coupled to transporting agent induces tolerance
|
|
US20040014698A1
(en)
*
|
2002-07-18 |
2004-01-22 |
Gonzalo Hortelano |
Oral administration of therapeutic agent coupled to transporting agent
|
|
US20040016013A1
(en)
*
|
2002-07-18 |
2004-01-22 |
Gonzalo Hortelano |
Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent
|
|
JP2004179274A
(ja)
*
|
2002-11-26 |
2004-06-24 |
Hitachi Ltd |
光半導体装置
|
|
US7655629B2
(en)
*
|
2002-12-19 |
2010-02-02 |
Ipf Pharmaceuticals Gmbh |
Peptides and their use for the treatment of HIV infections
|
|
US20050136437A1
(en)
*
|
2003-08-25 |
2005-06-23 |
Nastech Pharmaceutical Company Inc. |
Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
|
|
US20050208032A1
(en)
*
|
2004-01-16 |
2005-09-22 |
Gonzalo Hortelano |
Oral administration of therapeutic agent coupled to transporting agent
|
|
AU2005333165B2
(en)
|
2004-11-12 |
2012-07-19 |
Asuragen, Inc. |
Methods and compositions involving miRNA and miRNA inhibitor molecules
|
|
DE102005005528A1
(de)
*
|
2005-01-30 |
2006-08-03 |
Eberhard-Karls-Universität Tübingen Universitätsklinikum |
Injizierbares Mittel zur zielgerichteten Behandlung von retinalen Ganglienzellen
|
|
WO2007127219A2
(en)
*
|
2006-04-25 |
2007-11-08 |
Immune Disease Institute, Inc. |
Targeted delivery to leukocytes using protein carriers
|
|
ES2397439T3
(es)
|
2006-08-01 |
2013-03-07 |
Board Of Regents Of The University Of Texas System |
Identificación de un microARN que activa la expresión de la cadena pesada beta de la miosina
|
|
WO2008070135A2
(en)
|
2006-12-06 |
2008-06-12 |
Medimmune, Llc. |
Methods of treating systemic lupus erythematosus
|
|
EP2076590A4
(en)
|
2007-05-03 |
2011-06-01 |
Medimmune Llc |
SELF-IMMUNE DISEASE SELF-ANTIBODY MARKERS
|
|
CN101883576B
(zh)
|
2007-07-31 |
2015-08-19 |
得克萨斯系统大学董事会 |
调控纤维化的微小rna家族及其用途
|
|
EP2195341B1
(en)
|
2007-09-26 |
2017-03-22 |
UCB Biopharma SPRL |
Dual specificity antibody fusions
|
|
CN102036689B
(zh)
|
2008-03-17 |
2014-08-06 |
得克萨斯系统大学董事会 |
神经肌肉突触维持和再生中涉及的微小rna的鉴定
|
|
CA2737241C
(en)
*
|
2008-09-26 |
2017-08-29 |
Ucb Pharma S.A. |
Multivalent antibody fusion proteins
|
|
JP2012515532A
(ja)
|
2009-01-20 |
2012-07-12 |
ラモット アット テル アビブ ユニバーシティ， リミテッド |
Ｍｉｒ−２１プロモーター駆動性標的がん治療
|
|
AU2010236568B2
(en)
|
2009-04-14 |
2015-08-27 |
Société des Produits Nestlé S.A. |
Inflammatory bowel disease prognostics
|
|
WO2011030107A1
(en)
|
2009-09-10 |
2011-03-17 |
Ucb Pharma S.A. |
Multivalent antibodies
|
|
DK3252068T3
(da)
|
2009-10-12 |
2025-08-25 |
Larry J Smith |
Metoder og sammensætninger til modulering af genekspression ved anvendelse af oligonukleotidbaserede lægemidler administreret in vivo eller in vitro
|
|
WO2011060098A1
(en)
|
2009-11-10 |
2011-05-19 |
Prometheus Laboratories Inc. |
Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis
|
|
EP3214174B1
(en)
|
2010-03-04 |
2019-10-16 |
InteRNA Technologies B.V. |
A mirna molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with emt
|
|
EP2591106A1
(en)
|
2010-07-06 |
2013-05-15 |
InteRNA Technologies B.V. |
Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
|
|
EP2640470A4
(en)
*
|
2010-11-15 |
2016-02-17 |
Avon Prod Inc |
BIFUNCTIONAL ANTI-AGE COSMETICS ANCHORED WITH EXTENDED ACTION
|
|
EP2474617A1
(en)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
Mir for treating neo-angiogenesis
|
|
JP2015502740A
(ja)
|
2011-10-21 |
2015-01-29 |
ネステク ソシエテ アノニム |
炎症性腸疾患の診断を改善するための方法
|
|
US10174314B2
(en)
|
2011-12-22 |
2019-01-08 |
Interna Technologies B.V. |
MiRNA for treating head and neck cancer
|
|
EP2822600A4
(en)
|
2012-03-09 |
2016-04-06 |
Univ Northeastern |
METHOD OF DISTRIBUTING NUCLEIC ACID ANOPARTICLES TO THE CENTRAL NERVOUS SYSTEM FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
|
|
EP2917348A1
(en)
|
2012-11-06 |
2015-09-16 |
InteRNA Technologies B.V. |
Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
|
|
CA2896070A1
(en)
|
2012-12-21 |
2014-06-26 |
The Trustees Of Columbia University In The City Of New York |
Biomarkers for chronic traumatic encephalopathy
|
|
WO2014151551A1
(en)
|
2013-03-15 |
2014-09-25 |
Baylor Research Institute |
Ulcerative colitis (uc)-associated colorectal neoplasia markers
|
|
JP2016523980A
(ja)
|
2013-07-11 |
2016-08-12 |
ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク |
タウ発現を抑制するマイクロｒｎａ
|
|
US10172916B2
(en)
|
2013-11-15 |
2019-01-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating heart failure with agonists of hypocretin receptor 2
|
|
WO2015074010A2
(en)
|
2013-11-18 |
2015-05-21 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for cardiac regeneration
|
|
EP2960252A1
(en)
*
|
2014-06-26 |
2015-12-30 |
Institut Pasteur |
Phospholipase for treatment of immunosuppression
|
|
WO2017222911A1
(en)
|
2016-06-20 |
2017-12-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Circular rnas and their use in immunomodulation
|
|
US11958911B2
(en)
*
|
2017-02-10 |
2024-04-16 |
Shanghai Benemae Pharmaceutical |
Anti-coagulation factor XI antibody
|
|
JP6784973B2
(ja)
*
|
2017-03-30 |
2020-11-18 |
国立研究開発法人産業技術総合研究所 |
単層カーボンナノチューブ
|
|
US11590202B2
(en)
|
2017-04-11 |
2023-02-28 |
University Of Maryland, Baltimore |
Inhibitors of LTβR-NFκB signaling pathways for treating inflammation and cancer
|
|
CA3075532A1
(en)
|
2017-09-15 |
2019-03-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Multiplex production and barcoding of genetically engineered cells
|
|
EP3691655B1
(en)
|
2017-10-03 |
2021-09-01 |
Aptahem AB |
A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties
|
|
WO2019086603A1
(en)
|
2017-11-03 |
2019-05-09 |
Interna Technologies B.V. |
Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
|
|
CN109836500A
(zh)
*
|
2017-11-25 |
2019-06-04 |
深圳宾德生物技术有限公司 |
一种靶向dr5的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
|
|
US20250011787A1
(en)
|
2021-10-21 |
2025-01-09 |
The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads |
Retroelement-generated transcription factor decoys
|
|
WO2023081756A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
WO2023183588A1
(en)
|
2022-03-25 |
2023-09-28 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Methods of assessing engineered retron activity, and uses thereof
|
|
WO2023183589A1
(en)
|
2022-03-25 |
2023-09-28 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Rt-dna fidelity and retron genome editing
|
|
WO2023183627A1
(en)
|
2022-03-25 |
2023-09-28 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna
|
|
WO2023196725A1
(en)
|
2022-04-07 |
2023-10-12 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Continuous multiplexed phage genome engineering using a retron editing template
|
|
WO2024036232A2
(en)
*
|
2022-08-09 |
2024-02-15 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Bispecific antibodies and uses thereof
|
|
WO2024044673A1
(en)
|
2022-08-24 |
2024-02-29 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Dual cut retron editors for genomic insertions and deletions
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|